|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Colorectal cancer screening in Europe显示文摘Colorectal cancer(CRC)is the second most frequent malignant disease in Europe.Every year,412 000people are diagnosed with this condition,and 207 000patients die of it.In 2003,recommendations forscreening programs were issued by the Council of the European Union(EU),and these currently serve as thebasis for the preparation of European guidelines forCRC screening.The manner in which CRC screening iscarried out varies significantly from country to countrywithin the EU,both in terms of organization and thescreening test chosen.A screening program of onesort or another has been implemented in 19 of 27 EUcountries.The most frequently applied method is testing stool for occult bleeding(fecal occult blood test,FOBT).In recent years,a screening colonoscopy hasbeen introduced,either as the only method(Poland)orthe method of choice(Germany,Czech Republic). | Miroslav Zavoral Stepan Suchanek Filip Zavada Ladislav Dusek Jan Muzik Bohumil Seifert Premysl Fric | 2009 | World Journal of Gastroenterology2009,15,47: | 8 |
| 2 | Molecular biology of pancreatic cancer显示文摘In spite of continuous research efforts directed at early detection and treatment of pancreatic cancer, the outlook for patients affected by the disease remainsdismal. With most cases still being diagnosed at ad- vanced stages, no improvement in survival prognosis is achieved with current diagnostic imaging approaches. In the absence of a dominant precancerous condition, several risk factors have been identified including family history, chronic pancreatitis, smoking, diabetes mellitus, as well as certain genetic disorders such as hereditary pancreatitis, cystic fibrosis, familial atypical multiple mole melanoma, and Peutz-Jeghers and Lynch syn- dromes. Most pancreatic carcinomas, however, remain sporadic. Current progress in experimental molecular techniques has enabled detailed understanding of the molecular processes of pancreatic cancer development. According to the latest information, malignant pancre- atic transformation involves multiple oncogenes and tumor-suppressor genes that are involved in a variety of signaling pathways. The most characteristic aberrations (somatic point mutations and allelic losses) affect onco- genes and tumor-suppressor genes within RAS, AKT and Wnt signaling, and have a key role in transcription and proliferation, as well as systems that regulate the cell cycle (SMAD/DPC, CDKN2A/p16) and apoptosis (TP53). Understanding of the underlying molecular mechanisms should promote development of new methodology for early diagnosis and facilitate improvement in current ap- proaches for pancreatic cancer treatment. | Miroslav Zavoral Petra Minarikova Filip Zavada Cyril Salek Marek Minarik | 2011 | World Journal of Gastroenterology2011,17,24: | 6 |
| 3 | Comparative pollen morphology ofbrachylena,tarchananthus and two species of tubulifloridites(asteraceae)from the eocene,Knysna lignite of South Africa显示文摘 | Zavada M S Lowrey T K | 2010 | Review of palaeobotany and palynology2010,162,2: | 1 |
| 4 | Cyclosporine A or intra- venous cyclophosphamide for lupus nephritis: the Cyclofalune study显示文摘 | Zavada J Peisckov S Rysava R | 2010 | Lupus2010,19,11: | 1 |
| 5 | Genetic vari- ability of 15 autosomal STR loci in Russian populations显示文摘 | Stepanov VA Melnlkov AV Lash Zavada AY | 2010 | Leg Med (Tokyo)2010,12,5: | 1 |
| 6 | Tumor‐associated Carbonic Anhydrases and Their Clinical Significance显示文摘 | Silvia Pastorekova Seppo Parkkila Jan Zavada | 2006 | Advances in Clinical Chemistry2006,,: | 1 |
| 7 | Human tumor-associated cell adhesion protein MN/CA IX:identification of M75 epitope and of the region mediating cell adhesion显示文摘 | Zavada J Zavadova Z Pastorek J | 2000 | Br J Cancer2000,82,: | 1 |
| 8 | Cyclosporine A or intravenous cyclophosphamide for lupus nephritis:the Cyclofa-Lune study显示文摘 | Zavada J Pesickova S Rysava R | | 0,,11: | 1 |
| 9 | A Facile Synthesis of Hexakis(Bromomethyl) Benzene from Mesitylene显示文摘 | ZAVADA J PNKOVA M HOLY P | 1994 | Synthesis1994,110,11: | 1 |
| 10 | Cyclosporine A or intravenous cyclophosphamide for lupus nephritis:the Cyclofa-Lune study显示文摘 | Zavada J Pesickova S Rysava R | 2010 | Lupus2010,19,11: | 1 |
| 11 | Identification of the MN antigen as a diagnostic biomsrker of cervical intraepithelial nomas显示文摘 | Liao SY Brewer C Zavada J | 1994 | Am J Pathol1994,145,3: | 1 |
| 12 | Self - Assembly of 1,1 - Bipheny1-2,2,6,6 - tetracarboxylic Acid: Formation of an Achiral Grid with Chiral Compartments 显示文摘 | Holy P Zavada J Cysarova I Podlaha J | 1999 | Angew Chem Int Ed1999,38,: | 1 |
| 13 | Hydrogen incoporation and its temperature stability in SiC crystal 显示文摘 | Zavada J M Wilson R G Ren F | 1997 | Solid-state Electronics1997,41,: | 1 |
| 14 | Human tumor-associated cell adhension protein MN/CA IX : identification of M75 eptope and of the region mediating cell adhension 显示文摘 | Zavada J Zavadova Z Pastorek J | 2000 | Br J Cancer2000,82,11: | 1 |
| 15 | Pollen morphology of Ulmaceae显示文摘 | Zavada M | 1983 | Grana1983,22,: | 1 |
| 16 | Endoscopic Treatment of Chronic Pancreatitis: A Multicenter Study of 1000 Patients with Long-Term Follow-Up显示文摘 | T. R?sch S. Daniel M. Scholz K. Huibregtse M. Smits T. Schneider C. Ell G. Haber J.-F. Riemann R. Jakobs R. Hintze A. Adler H. Neuhaus M. Zavoral F. Zavada V. Schusdziarra N. Soehendra | 2002 | Endoscopy2002,,10: | 1 |
| 17 | Residual surface roughness of diamond-turned optics显示文摘 | Zavada J M | 1975 | Applied Optics1975,14,8: | 1 |
| 18 | Biodistri- bution and Pharmacokinetics of ^125I-Labeled Monoclonal Antibody M75 Specific for Carbonic Anhydrase Ⅸ, an Intrinsic Marker of Hypoxia, in Nude Mice Xenografted With Human Colorectal Carcinoma显示文摘 | Chrastina A Zavada J Parkkila S | 2003 | Int J Cancer2003,105,6: | 1 |
| 19 | Electrically programmable photonic crystal slab based on the metal insulator transition in VOz 显示文摘 | X1AO D KIM K W ZAVADA J M | 2005 | Journal of Applied Physics2005,97,10: | 1 |
| 20 | Tumor-associated carbonic anhydrases and their clinical significance显示文摘 | Pastorekova S Parkkila S Zavada J | 2006 | Adv Clin Chem2006,42,: | 1 |